MA40371B1 - Sélectivité efficace des protéines recombinées - Google Patents

Sélectivité efficace des protéines recombinées

Info

Publication number
MA40371B1
MA40371B1 MA40371A MA40371A MA40371B1 MA 40371 B1 MA40371 B1 MA 40371B1 MA 40371 A MA40371 A MA 40371A MA 40371 A MA40371 A MA 40371A MA 40371 B1 MA40371 B1 MA 40371B1
Authority
MA
Morocco
Prior art keywords
recombinant proteins
methods
expression
mammalian
relates
Prior art date
Application number
MA40371A
Other languages
English (en)
Other versions
MA40371A (fr
Inventor
Dipali Deshpande
Darya Burakov
Gang Chen
James Fandl
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA40371A publication Critical patent/MA40371A/fr
Publication of MA40371B1 publication Critical patent/MA40371B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Cette invention concerne un nouveau système d'expression comprenant un marqueur de mammifère sélectionnable qui favorise les modifications post-traductionnelles souhaitables des glycoprotéines. En particulier, l'invention concerne des procédés et des compositions permettant une expression optimale des protéines recombinées dans des cellules de mammifères par utilisation d'un système de marqueur de sélection basé sur des gènes gpt d'origine mammifère. L'invention concerne également des procédés qui facilitent la sélectivité, des copies d'expression améliorées ainsi qu'un rendement protéique des protéines recombinées amélioré dans des cellules de mammifères, ainsi que des procédés d'utilisation des systèmes d'expression gpt.
MA40371A 2014-08-19 2015-08-19 Sélectivité efficace des protéines recombinées MA40371B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462039416P 2014-08-19 2014-08-19
PCT/US2015/045793 WO2016028838A1 (fr) 2014-08-19 2015-08-19 Sélectivité efficace des protéines recombinées

Publications (2)

Publication Number Publication Date
MA40371A MA40371A (fr) 2017-06-28
MA40371B1 true MA40371B1 (fr) 2021-03-31

Family

ID=55347784

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40371A MA40371B1 (fr) 2014-08-19 2015-08-19 Sélectivité efficace des protéines recombinées

Country Status (26)

Country Link
US (4) US9732357B2 (fr)
EP (2) EP3901274A1 (fr)
JP (3) JP7115851B2 (fr)
KR (2) KR102406976B1 (fr)
CN (2) CN107075549B (fr)
AR (1) AR102333A1 (fr)
AU (3) AU2015305565B9 (fr)
CA (1) CA2957036A1 (fr)
CY (1) CY1124079T1 (fr)
DK (1) DK3183359T3 (fr)
EA (1) EA035340B1 (fr)
ES (1) ES2849728T3 (fr)
HR (1) HRP20210301T1 (fr)
HU (1) HUE054069T2 (fr)
IL (3) IL287020B (fr)
LT (1) LT3183359T (fr)
MA (1) MA40371B1 (fr)
MX (2) MX2017002203A (fr)
MY (1) MY191745A (fr)
PL (1) PL3183359T3 (fr)
PT (1) PT3183359T (fr)
RS (1) RS61371B1 (fr)
SG (2) SG10201707859RA (fr)
SI (1) SI3183359T1 (fr)
TW (3) TWI777374B (fr)
WO (1) WO2016028838A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR102333A1 (es) 2014-08-19 2017-02-22 Regeneron Pharma Selectividad eficiente de proteínas recombinadas
US20200385710A1 (en) * 2018-02-08 2020-12-10 Applied Stemcell, Inc. Methods for screening variant of target gene
WO2021079909A1 (fr) 2019-10-23 2021-04-29 キヤノン株式会社 Procédé de production d'un article en céramique, et article en céramique

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
US5972650A (en) 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
ATE325865T1 (de) 2001-01-16 2006-06-15 Regeneron Pharma Isolierung von sezernierte proteine exprimierenden zellen
DK1492874T3 (da) 2002-03-29 2011-03-14 Xoma Technology Ltd Multigene vektorplasmider og fremgangsmåder til forøgelse af ekspressionen af rekombinante polypeptider
US8673589B2 (en) 2002-05-29 2014-03-18 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
US7384744B2 (en) 2002-11-29 2008-06-10 Boehringer Ingelheim Pharma Gmbh & Co., Kg Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
JP2005027599A (ja) 2003-07-09 2005-02-03 Nara Institute Of Science & Technology 植物由来遺伝子を用いた遺伝子導入植物の選抜法
EP1586585A1 (fr) * 2004-04-14 2005-10-19 F. Hoffmann-La Roche Ag Système d'expression pour la production des protéines de fusion IL-15/Fc et leur utilisation
EP2094831B1 (fr) 2006-12-07 2015-09-16 Dow AgroSciences LLC Nouveaux gènes marqueurs sélectionnables
WO2008151219A1 (fr) 2007-06-04 2008-12-11 Regeneron Pharmaceuticals, Inc. Régions d'expression et de stabilité amplifiées
KR100927803B1 (ko) * 2007-11-23 2009-11-23 한국생명공학연구원 식물 형질전환체를 선별하기 위한 마커로서 ｇｐｔ 유전자
WO2009071696A2 (fr) * 2007-12-07 2009-06-11 Zymogenetics, Inc. Molécules d'anticorps humanisés spécifiques pour il-31
WO2009131681A2 (fr) * 2008-04-22 2009-10-29 Rutgers, The State University Compositions de produit de construction e2 de vhc et procédés correspondants
EP3037529B1 (fr) * 2008-12-09 2019-03-27 Halozyme, Inc. Polypeptides ph20 solubles étendus et leurs utilisations
EP2674495A1 (fr) 2012-06-14 2013-12-18 Sanofi Système d'expression dans CHO
AR102333A1 (es) * 2014-08-19 2017-02-22 Regeneron Pharma Selectividad eficiente de proteínas recombinadas

Also Published As

Publication number Publication date
KR20170055481A (ko) 2017-05-19
AU2023200752A1 (en) 2023-03-09
PL3183359T3 (pl) 2021-08-02
IL287020B (en) 2022-09-01
JP2017525368A (ja) 2017-09-07
EP3183359B1 (fr) 2020-12-16
IL287020A (en) 2021-12-01
IL250531A0 (en) 2017-03-30
MX2021009154A (es) 2021-09-10
CN107075549B (zh) 2021-04-20
MA40371A (fr) 2017-06-28
HRP20210301T1 (hr) 2021-04-02
US20160053280A1 (en) 2016-02-25
TW202246506A (zh) 2022-12-01
JP7561232B2 (ja) 2024-10-03
JP7115851B2 (ja) 2022-08-09
PT3183359T (pt) 2021-02-03
AU2023200752B2 (en) 2024-02-29
AU2020205336A1 (en) 2020-08-06
TWI719945B (zh) 2021-03-01
KR102406976B1 (ko) 2022-06-10
KR102556383B1 (ko) 2023-07-17
RS61371B1 (sr) 2021-02-26
AR102333A1 (es) 2017-02-22
BR112017003074A2 (pt) 2018-03-06
LT3183359T (lt) 2021-02-25
KR20220080215A (ko) 2022-06-14
TW202124716A (zh) 2021-07-01
AU2015305565B9 (en) 2020-05-21
EP3901274A1 (fr) 2021-10-27
CN113293139A (zh) 2021-08-24
TWI777374B (zh) 2022-09-11
US10457959B2 (en) 2019-10-29
AU2015305565B2 (en) 2020-04-30
EA035340B1 (ru) 2020-05-29
IL295361B2 (en) 2023-08-01
JP7260510B2 (ja) 2023-04-18
US20210340564A1 (en) 2021-11-04
CY1124079T1 (el) 2022-05-27
SG11201701121UA (en) 2017-03-30
EP3183359A4 (fr) 2018-04-04
MY191745A (en) 2022-07-13
CA2957036A1 (fr) 2016-02-25
AU2015305565A1 (en) 2017-03-09
IL295361A (en) 2022-10-01
CN107075549A (zh) 2017-08-18
US20170335341A1 (en) 2017-11-23
IL295361B1 (en) 2023-04-01
DK3183359T3 (da) 2021-02-01
SG10201707859RA (en) 2017-10-30
TW201615833A (zh) 2016-05-01
EP3183359A1 (fr) 2017-06-28
HUE054069T2 (hu) 2021-08-30
MX2017002203A (es) 2017-05-22
US9732357B2 (en) 2017-08-15
US11085053B2 (en) 2021-08-10
SI3183359T1 (sl) 2021-03-31
WO2016028838A1 (fr) 2016-02-25
EA201790241A1 (ru) 2017-06-30
ES2849728T3 (es) 2021-08-20
JP2023076667A (ja) 2023-06-01
IL250531B (en) 2021-10-31
JP2020174681A (ja) 2020-10-29
US20200063159A1 (en) 2020-02-27
AU2020205336B2 (en) 2022-11-10
TWI832364B (zh) 2024-02-11

Similar Documents

Publication Publication Date Title
MA40309A1 (fr) Anticorps anti-cd73 et leurs utilisations
MX2018005389A (es) Animales no humanos que tienen un gen 3 de activacion linfocitaria humanizado.
EA201890790A1 (ru) Связывающие pd-1 белки и способы их применения
EA202090931A3 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
PH12016500342A1 (en) Non-human animals having a humanized signal-regulatory protein gene
WO2016130704A3 (fr) Procédés et compositions pour analyser des composants cellulaires
EA202192126A3 (ru) Способы сбора культур клеток млекопитающих
MX2017007293A (es) Animales no humanos que tienen un gen del grupo de diferenciacion 47 humanizado.
AU2016259730A8 (en) Claudin-18.2-specific immunoreceptors and T cell epitopes
MX2017008817A (es) Composiciones y metodos para la glicosilacion de proteinas.
MX2017009538A (es) Antigenos de citomegalovirus y su uso.
MX2017007636A (es) Animales no humanos que tienen un gen del grupo de diferenciacion 274 humanizado.
CA3011049A1 (fr) Compositions pour lier des domaines de liaison a l'adn et des domaines de clivage
ZA202208710B (en) Anti-vegf protein compositions and methods for producing the same
EA201791918A1 (ru) Модификация белков клеток-хозяев
EP4219729A3 (fr) Compositions et procédés pour le ciblage efficace de transgènes
MX2020012356A (es) Sobreexpresion de reguladores de la ruta de n-glicosilacion para modular la glicosilacion de proteinas recombinantes.
CR20180445A (es) Inmunoglobulinas diseñadas por ingeniería genética con unión alterada al fcrn
CY1124079T1 (el) Αποτελεσματικη επιλεκτικοτητα των ανασυνδυασμενων πρωτεϊνων
MX2021001418A (es) Produccion de proteinas heteromultimericas usando celulas de mamifero.
EA201691691A1 (ru) Белки слияния tatk-cdkl5, их композиции, составы и применение
MX2018011193A (es) Proteinas derivadas de alfa-1-microglobulina novedosas y su uso.
MX2018003445A (es) Expresion de proteinas que contienen fc.
MX2018001687A (es) Metodos y sistemas para extraer proteina de acido oxalico reducido de especies acuaticas y composiciones de la misma.
MX2020012016A (es) Sistemas y metodos para cuantificar y modificar la viscosidad de proteinas.